INNOVIVA, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
INNOVIVA, INC. (INVA) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $22.39 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-05-05
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was $22.39M, a 91.52% increase year-over-year.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was $11.69M.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2014-03-31 was $14.13M.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2013-12-31 was -$1.43M, a 1076.71% decline year-over-year.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was -$219.58M.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$58.28M.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2011 was -$55.82M.
- INNOVIVA, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2010 was -$40.31M, a 2422.12% decline from fiscal 2009.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-03-31 | $22.39M 10-Q · filed 2017-05-05 | |||
| 2016-03-31 | $11.69M 10-Q · filed 2017-05-05 | |||
| 2014-03-31 | $14.13M 10-Q · filed 2014-05-07 | $12.70M derived: sum of 2 quarters · filed 2014-05-07 | -$86.91M derived: sum of 3 quarters · filed 2014-05-07 | -$160.44M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$101.03M derived: sum of 2 quarters · filed 2014-03-03 | -$174.57M derived: sum of 3 quarters · filed 2014-03-03 | -$219.58M 10-K · filed 2014-03-03 |
| 2013-09-30 | -$99.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | -$173.14M derived: sum of 2 quarters · filed 2013-11-01 | -$218.15M 10-Q · filed 2013-11-01 | -$218.01M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-06-30 | -$73.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$118.55M 10-Q · filed 2013-08-01 | -$118.40M derived: sum of 3 quarters · filed 2014-05-07 | -$152.11M derived: sum of 4 quarters · filed 2014-05-07 |
| 2013-03-31 | -$45.01M 10-Q · filed 2014-05-07 | -$44.87M derived: sum of 2 quarters · filed 2014-05-07 | -$78.58M derived: sum of 3 quarters · filed 2014-05-07 | -$111.68M derived: sum of 4 quarters · filed 2014-05-07 |
| 2012-12-31 | $146.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$33.57M derived: sum of 2 quarters · filed 2014-03-03 | -$66.67M derived: sum of 3 quarters · filed 2014-03-03 | -$58.28M 10-K · filed 2014-03-03 |
| 2012-09-30 | -$33.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-01 | -$66.81M derived: sum of 2 quarters · filed 2013-11-01 | -$58.43M 10-Q · filed 2013-11-01 | -$53.88M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-06-30 | -$33.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$24.72M 10-Q · filed 2013-08-01 | -$20.17M derived: sum of 3 quarters · filed 2014-03-03 | -$30.07M derived: sum of 4 quarters · filed 2014-03-03 |
| 2012-03-31 | $8.38M 10-Q · filed 2013-05-01 | $12.93M derived: sum of 2 quarters · filed 2014-03-03 | $3.03M derived: sum of 3 quarters · filed 2014-03-03 | -$46.20M derived: sum of 4 quarters · filed 2014-03-03 |
| 2011-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$5.35M derived: sum of 2 quarters · filed 2014-03-03 | -$54.58M derived: sum of 3 quarters · filed 2014-03-03 | -$55.82M 10-K · filed 2014-03-03 |
| 2011-09-30 | -$9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-31 | -$59.13M derived: sum of 2 quarters · filed 2012-10-31 | -$60.37M 10-Q · filed 2012-10-31 | -$78.40M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | -$49.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$50.47M 10-Q · filed 2012-08-01 | -$68.50M derived: sum of 3 quarters · filed 2013-02-26 | |
| 2011-03-31 | -$1.24M 10-Q · filed 2012-05-02 | -$19.27M derived: sum of 2 quarters · filed 2013-02-26 | ||
| 2010-12-31 | -$18.03M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$40.31M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | -$22.28M 10-Q · filed 2011-11-02 | |||
| 2009-12-31 | $1.74M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |